PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1684437
PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1684437
Immunohematology Market size was valued at US$ 2,609.43 Million in 2024, expanding at a CAGR of 7.82% from 2025 to 2032.
Immunohematology, more often referred to as blood banking or transfusion medicine, is the area of hematology and immunology that studies antigens and antibodies related to blood. This is one of the most indispensable healthcare fields, mainly focused on the identification and compatibility of blood for transfusions, and understanding the disorders that might be associated with immune reactions in the blood. The general theme for this field refers to the detection, characterization, and clinical implications of blood group antigens and their corresponding antibodies. The immunohematology foundation lies in ABO and Rh blood group systems, which are critical for blood compatibility determination. Immunohematology tests entail cross-matching, screening irregular antibodies, and detecting antigens predisposing individuals to adverse reactions related to transfusions or pregnancy. Such includes the hemolytic disease of the fetus and the newborn. Modern medicine could hardly do without it since applying blood and other blood products guarantees the treatment of numerous diseases- from traumas and surgeries, through anemias, to chronic diseases.
Immunohematology Market- Market Dynamics
The immunohematology market is driven by increased incidence of hematological disorders and chronic diseases. According to the World Health Organization, anemia has affected around 1.62 billion people globally. Such cases emphasize the importance of advanced blood testing and transfusion services. Moreover, the increased number of surgical procedures worldwide contributes to the demand for blood products & immunohematology services. Propelling awareness and government initiatives promoting blood donation have increased the availability of blood products, thereby stimulating market expansion. Incorporating next-generation sequencing and polymerase chain reaction (PCR) has improved the accuracy of immunohematology diagnostics, encouraging increased adoption in clinical settings.
Emerging markets hold significant growth potential for the immunohematology industry. Developing countries' investment in healthcare infrastructure would be targeted towards improving diagnostics & blood transfusion services. Moreover, with the increasing popularity of personalized medicine and the patient-specific approach toward blood management, specialized immunohematology products and services can find a scope in the market. Public-private collaborations to increase blood donation awareness and safety standards will also favor market growth. However, the high costs for advanced diagnostic equipment and the highly skilled personnel operating complex diagnostic instruments will likely hinder the market. Furthermore, regulations often very stringent concerning blood products and diagnostic devices usually delay product registration and entry to the market, possibly affecting the prompt availability of new solutions.
Immunohematology Market- Key Insights
Reagents segment is the largest in the market, because of their immense usage in blood typing and cross-matching, one of the reasons being the growth in demand for quality and reliable reagents.
Hospitals are the largest segment of the immunohematology market since hospitals have modern diagnostic facilities and skilled personnel who can perform intricate immunohematology tests for patient management.
North America leads the market, based on a better-established healthcare structure, a more significant number of blood transfusion procedures, and leadership of top competition.
Asia Pacific is growing fastest due to continuous improvement in health systems, blood donation awareness among the population, and health technology investment push.
The Global Immunohematology Market is segmented on the basis of Type, Application, End User, and Region.
By type, the immunohematology market is divided into analyzers and reagents. The reagent segment dominates the market. Blood grouping, cross-matching, and the screening process depend on reagents; hence, it gains the domination power. Increased incidence of hematological disease in the patient population, together with the frequency of blood transfusions, has highly demanded that blood banks depend upon the blood banking reagent kits having increased accuracy levels in the reagent kits. Widespread usage in hospitals, blood banks, and diagnostic laboratories for ensuring compatibility in blood transfusions and managing hemolytic diseases has emphasized the importance of these reagents. The analyzers segment is expected to grow the fastest during the forecast period. This is due to the growing demand for automated & semi-automated analyzers that offer better precision, quicker turnaround times, and efficient workflow in blood testing procedures. The global trend towards automation in laboratories has been one of the most significant factors driving the growth of the analyzers segment.
By end use, the immunohematology market is divided into blood banks, hospitals, diagnostic and reference laboratories, and academic and research institutes. Hospitals are the largest segment of the immunohematology market. This is because hospitals are critical in patient care, where blood typing, cross-matching, and transfusion services are often essential during surgery and trauma. Hospitals also have modern diagnostic facilities and skilled personnel who can perform intricate immunohematology tests for patient management. The blood banks segment is projected to exhibit the highest CAGR during the forecast period. This is mainly due to heightened awareness and associated programs encouraging people to opt for voluntary donations, followed by an expansion of blood banks and collection centers. Blood banks have become unavoidable as they constitute and sustain a secured adequate supply and need to avail themselves of the latest immunohematology in their operations to detect infections while being compatible. Development in blood banks- especially in third-world countries, allows for increased penetration of safe blood transfusions, further propelling market growth.
Immunohematology Market- Geographical Insights
The North American market dominates, having a substantial presence. Advanced infrastructure of healthcare delivery systems and maximum utilization of technology with significant amounts of transfusion per annum explain the share here. The United States is claimed to transfuse an average of around 14.6 million units every year in blood as transcribed by the CDC, marking this region very highly for requiring products and services related to immunohematology. Leading nations contributing to this market include the US & Canada, known for their solid healthcare systems and continuous investment in medical innovations. The Asia-Pacific region is expected to experience the fastest growth during the forecast period. This is due to propelling healthcare expenditure, increased awareness regarding blood donation, and increased blood-related disorders. Countries such as India & China have recently improved their health infrastructure & blood transfusion services, with the WHO observing that such changes are increasing. These trends put countries like China, India, and Japan at the forefront of this growing market and are likely to continue with much improvement in the practice of immunohematology.
The global immunohematology market is highly competitive, with the presence of a few key players who are driving innovation and expanding their market footprint. The leading companies in the market include Bio-Rad Laboratories, Inc., Immucor, Ortho Clinical Diagnostics, Grifols, and BD (Becton Dickinson), which have dominated the market due to their extensive product portfolios & robust distribution networks. These players focus on developing advanced immunohematology solutions, such as automated analyzers, reagents, and molecular diagnostics, to enhance diagnostic accuracy & efficiency. Strategic collaborations, mergers, and acquisitions are common strategies used to expand product offerings and penetrate emerging markets. Companies are also able to provide increasing markets in Asia-Pacific and Latin America by partnering with healthcare institutions and blood banks. Investments in research and development, aiming to develop new-generation immunohematology technologies, add to the market's competitive landscape. This dynamic environment is likely to propel further developments in the immunohematology sector.
April 2024: Grifols launched the Erytra Eflexis automated blood-typing technology in the Chinese market after approval from the appropriate authorities. It automates processes in blood typing and enhances efficiency at blood banks.
May 2023: Bio-Rad Laboratories, Inc. launched the IH-500TM NEXT System, an automated ID-Card system. The system is an improvement of blood type testing sensitivity as well as screening for antibodies.
November 2023: Versiti bought Pearl Pathways, a Indianapolis-based blood management software company. This will help Versiti improve their digital capabilities and better manage the blood supply chain.
July 2023: QuidelOrtho partners with BYG4lab to enrich its Informatics Offerings. The collaboration will focus on creating new software products for blood banks and transfusion centers.